

facts about COMBINATION IMMUNOTHERAPY for kidney cancer.




Immunotherapy is a **cancer treatment** that boosts the body's own immune system to fight cancer. **Combination Immunotherapy** uses immunotherapy with other therapies to fight **kidney cancer**.

WHY USE COMBINATION IMMUNOTHERAPY?


Combination immunotherapy can help the immune system attack cancer cells better than with one drug alone.

Immunotherapy includes antibodies, vaccines, viruses and other agents to make the immune system attack cancer cells.

Combination Immunotherapy is when more than one type of **checkpoint inhibitor** is combined to better block certain proteins.



Immunotherapy used for advanced RCC include interleukin-2 (IL-2), nivolumab, ipilimumab, pembrolizumab, avelumab.




Immune checkpoint inhibitors are antibodies given intravenously to block the "checkpoints" that cancer cells use to avoid being attacked by the immune system. This combination helps the body attack cancer cells.



Examples include: axitinib and avelumab, axitinib and pembrolizumab, bevacizumab and atezolizumab

RISKS AND BENEFITS

of combination immunotherapy for *kidney cancer patients*.



While patients can benefit, there is a risk that healthy cells may be targeted. Autoimmune problems are usually manageable but, in rare cases, can be serious.

- Kidney cancer is among the 10 **most common** cancers in the U.S.
- 90% of kidney cancers are **renal cell carcinoma (RCC)**.
- 15% of patients using a combination immunotherapy to treat RCC **lived longer** than with one treatment.
- 9% of patients with advanced RCC were found to have **"no more signs of cancer"** after using combination immunotherapy in a clinical test.

BROUGHT TO YOU BY THE

Urology Care
FOUNDATION™
The Official Foundation of the
American Urological Association

For more information about kidney cancer and immunotherapy, visit the Urology Care Foundation's website:

UrologyHealth.org

Supported by an independent educational grant from Merck & Co., Inc.